Perrigo Recasts Financials with New Product-Based Reporting Segments
summarizeSummary
Perrigo has adopted new product-based reporting segments and recast historical financials for comparability, providing a new framework for investor analysis.
check_boxKey Events
-
New Reporting Segments Adopted
Perrigo transitioned from geographic to product category-based reporting, establishing "Self Care," "Specialty Care," and "Infant Formula" segments, effective Q1 2026.
-
Recast Historical Financials Provided
Exhibit 99.1 includes unaudited recast financial metrics for 2024 and 2025 under the new segment structure, aiding comparability for future reporting.
-
Profitability Measure Changed
The primary measure for evaluating segment profitability has shifted from segment operating income to segment adjusted operating income.
-
No Impact on Historical Consolidated Results
The company explicitly stated that these reporting changes have no impact on its historical consolidated financial position, results of operations, or cash flows.
auto_awesomeAnalysis
Perrigo Company plc has implemented a significant change to its financial reporting structure, moving from a geographic-based model to a product category-based one. This update, which includes new "Self Care," "Specialty Care," and "Infant Formula" segments, is crucial for investors as it provides a new lens through which to analyze the company's operational performance and strategic priorities. The company also shifted its primary measure for segment profitability to "adjusted operating income." While these changes do not impact historical consolidated financial results, the provision of recast historical data in Exhibit 99.1 is essential for analysts to update their models and ensure comparability for future reporting periods. This filing follows the initial announcement of the segment change on February 26, 2026, and provides the detailed financial re-segmentation.
At the time of this filing, PRGO was trading at $11.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.